Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

Atzpodien, J

Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). [electronic resource] - British journal of cancer Aug 2006 - 463-9 p. digital

Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0007-0920

10.1038/sj.bjc.6603271 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Capecitabine
Carcinoma, Renal Cell--drug therapy
Deoxycytidine--administration & dosage
Disease Progression
Disease-Free Survival
Female
Fluorouracil--administration & dosage
Germany
Humans
Interferon alpha-2
Interferon-alpha--administration & dosage
Interleukin-2--administration & dosage
Isotretinoin--administration & dosage
Kidney Neoplasms--drug therapy
Lung Neoplasms--secondary
Male
Middle Aged
Recombinant Proteins
Survival Analysis